A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy

Lipohypertrophy in HIV-infected patients is associated with metabolic abnormalities. Raltegravir (RAL) is not known to induce fat changes or severe metabolic perturbations. HIV-infected women with central adiposity and HIV-1 RNA less than 50 copies per milliliter on non-nucleoside reverse transcript...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lake, Jordan E., McComsey, Grace A., Hulgan, Todd M., Wanke, Christine A., Mangili, Alexandra, Walmsley, Sharon L., Boger, M. Sean, Turner, Ralph R., McCreath, Heather E., Currier, Judith S.
Format: Artigo
Idioma:Inglês
Publicat: Mary Ann Liebert, Inc. 2012
Matèries:
Clinical and Epidemiologic Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3426192/
https://ncbi.nlm.nih.gov/pubmed/22823027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/apc.2012.0135
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars